Participated · Series A · Feb 2026

Starget Pharma operates in the United States and Israel and focuses on developing peptide-based radioligand therapies (RLTs) for oncology indications. Its proprietary in-silico, AI-driven discovery platform rapidly identifies and prioritizes radioligand candidates, positioning the company as, in management’s words, the only RLT firm with an AI-powered peptide discovery engine. The lead program is a first-in-class SSTR3-targeted theranostic pair intended for sarcoma, neuroendocrine tumors, and malignant melanoma. A strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT) supplies downstream capabilities in imaging, radiochemistry, clinical research, and manufacturing, creating an end-to-end pathway from discovery through early-phase trials. Multiple clinical entries are planned for 2026, supported by newly secured capital to expand U.S. translational and manufacturing infrastructure. Though still pre-revenue, the company’s clinical-stage designation and AI platform aim to generate a repeatable pipeline of RLT programs.

Led · Equity · Jan 2026

KAHR Bio is a clinical-stage biotechnology company based in Modi’in, Israel that creates dual-targeting fusion protein therapeutics designed to activate both the innate and adaptive immune systems within the tumor microenvironment. Its lead candidate, DSP107, is a first-in-class bispecific CD47×4-1BB T-cell engager that anchors to CD47-expressing tumor cells while delivering a potent 4-1BB co-stimulatory signal to recruit and activate cytotoxic T cells. Across more than 130 treated patients, DSP107 has shown a favorable safety and tolerability profile. In a Phase 2a study of heavily pre-treated metastatic microsatellite stable colorectal cancer (MSS-CRC), DSP107 combined with atezolizumab achieved a 17.5-month median overall survival, outperforming the 6.4–10.8 months generally seen with approved therapies, even though 75% of patients had liver metastases. Encouraged by these data, the company has launched a randomized, controlled Phase 2b trial comparing DSP107 plus atezolizumab to fruquintinib in fourth-line MSS-CRC, with interim results expected in late 2026 and topline data in the second half of 2027. Proceeds from its latest financing and an accompanying debt facility are intended to fully fund this Phase 2b program and other R&D activities.

Led · Equity · Mar 2024

Eisbach is a clinical-stage biotechnology company based in Martinsried, Germany, focused on precision oncology. It develops allosteric drugs and uses its proprietary ALLOS discovery platform to target molecular machines involved in tumor genome reorganization and exploit synthetic lethality in defined tumors. The company's lead candidate, EIS-12656, is described as a first-in-class small molecule that shuts down the molecular process that reorganizes the tumor genome upon DNA damage and PARP activation. EIS-12656 demonstrated promising preclinical activity and an exceptional safety profile according to the company. Eisbach plans a Phase 1/2 clinical trial of EIS-12656 to be conducted at MD Anderson. The company recently received $4.5M from Cancer Focus Fund to support that clinical program. Eisbach Bio develops novel allosteric inhibitors that disrupt molecular machines involved in disease, with programs in oncology and antivirals. The company identified synthetic‑lethal and oncogenic helicases as cancer targets and has a SARS‑CoV‑2 Nsp13 helicase inhibitor as its COVID‑19 therapeutic candidate. Eisbach completed preclinical development of the antiviral and is progressing IND‑enabling work. The company received EUR 8 million in government funding to support clinical development through Phase I/II. It expects to initiate Phase I clinical trials for the COVID‑19 asset in Q1 2022. Eisbach was founded in 2019, is privately held, and is backed by international investors.

Led · Equity · Nov 2023

March Biosciences is developing MB-105, a CD5-targeted CAR-T cell therapy aimed at relapsed and refractory T cell lymphoma; MB-105 has orphan drug designation and is in a Phase 2 trial. The company emphasizes a shorter, simpler, and more robust manufacturing process and has partnered with Cell Therapy Manufacturing Center (CTMC) and Volnay Therapeutics to address manufacturing risk. March positions itself as the most advanced cell therapy product in the T cell lymphoma space and plans to expand its pipeline into additional indications. Management estimates a US addressable market of about $6 billion annually, with the initial indication representing roughly $3 billion. The company has faced a challenging fundraising environment and has focused on clinical data and manufacturing de-risking to attract partners and investors. Financially, March has sufficient resources to complete its company-sponsored Phase 2a and pursue additional pipeline development based on its recent financing runway. March Biosciences is a Houston, TX-based clinical-stage biotechnology company led by CEO Sarah Hein focused on addressing cancers unresponsive to current immunotherapies. Its lead asset, MB-105, is a chimeric antigen receptor T-cell (CAR-T) therapy targeting CD5, a protein widely expressed in both normal and malignant T-cells including T-cell leukemias and lymphomas. Because CD5 is present on healthy T-cells, it has been a challenging target; MB-105 has been engineered to preserve healthy T-cells while maintaining potency against CD5-positive tumor cells. MB-105 is being evaluated in an ongoing Phase 1 trial conducted by the Baylor College of Medicine Cell and Gene Therapy Center, where it has demonstrated a favorable safety profile and encouraging early efficacy in relapsed T-cell lymphoma and T-cell acute lymphoblastic leukemia patients. The company intends to use new funding to accelerate an upcoming Phase 2, open-label, multi-center trial assessing MB-105 in CD5-positive relapsed/refractory T-cell lymphoma; patients will receive one dose and be followed for a minimum of 12 months. March Biosciences raised $4.8M from Cancer Focus Fund.

Led · Equity · Jun 2023

ImmunoGenesis is a clinical-stage biotechnology company developing IMGS-001, a dual-specific PD-L1/PD-L2 antibody engineered with cytotoxic effector function to target immune-excluded tumors. IMGS-001 is designed to block PD-L1 and PD-L2 and kill immunosuppressive cells in the tumor microenvironment, potentially overcoming resistance to existing immunotherapies. Preclinical data reportedly showed substantially higher response rates versus currently available immunotherapies. The company has licensed the technology from discoveries at MD Anderson and the ORBIT platform (licensed in 2019). ImmunoGenesis is advancing IMGS-001 into a first-in-human Phase 1a/1b multi-site study that will evaluate safety, tolerability, PK, immunogenicity, and preliminary anti-tumor activity, with Phase 1b focused on immune-resistant tumors such as ovarian, colorectal, and triple negative breast cancers. Funding announced from the Cancer Focus Fund will support the MD Anderson portion of the trial and coincides with an expected Series A financing in Q3.